Compare MasTec Inc (MTZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Neurocrine Biosciences Inc — how do they compare? MasTec Inc trades at $350.55 (market cap $26.60B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: MasTec Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | NBIX | |
|---|---|---|
Market Cap | $26.60B | $17.40B |
Sector | Technology | Health |
52-Week High | $437.51 | $180.55 |
52-Week Low | $172.51 | $123.10 |
Enterprise Value | $29.34B | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
